‘At risk’ promoter haplotypes in VEGF, which predict reduced expression of bioavailable isoforms, have been described in some European ALS populations [7] and combined with evidence from animal models, the data suggest that VEGF isoforms have a neuromodulatory and neuroprotective role in the CNS. This evidence concerns the gene VEGFA and amyotrophic lateral sclerosis.